Pharmacotherapy for Hematological Disorders

Running header:

Pharmacotherapyfor Hematological Disorders

Hemophiliadisease condition affects the normal blood clotting ability of thebody. This condition is genetically passed down from the parents tothe offspring. This pathological condition can be as a result ofdefects in the blood vessels, the coagulation mechanisms or the bloodplatelets. In the instance of an injury to the blood vessels or asurgery, a hemophilic individual bleeds for longer than a healthyperson. Due to the development seen currently in the health sectorsaround the world several methods have been improvised to help treathemophilia and restore life. Currently, the most preferred method oftreatment is the replacement therapy. This is achieved by injectingthe missing protein factor into the patient’s veins where the bodyimmediately utilizes it in the clotting cascade and stops bleeding(Allen F.Shaughnessy, 2008).

Severaldrugs with different target effect can be directed towards stoppingbleeding in a hemophilic. This condition is not curable thus itrequire good monitoring to ensure life is not lost. The followingdrugs are therefore used to ensure treat this conditions. The firstgroup includes clot preserving drugs called antifibrinolytics. Theyare commonly used during surgery to prevent the fibrin network frombreaking thus preserving blood loss. They include aprotinin,tranexamic acid (TXA) and epsilon-aminocaproic acid used followingacute traumatic injury (Ian Roberts, 2012).

Anothergroup is the fibrin sealant which is usually applied directly to thewound site to promote clotting and healing. They are made to containeither much fibrinogen on thrombin that helps to form stronger clotsand stimulation of clot formation respectively. The mostly usedexamples are the fresh frozen plasma prepared by coprecipitation (IanRoberts, 2012).

Geneticsas the study of genes in living organisms has turned out to have awider influence of 20-90% on pharmacokinetics and pharmacodynamics.Genetic polymorphism of drug enzymes affects the drug efficacy duringtreatment. Some patients under the same treatment conditions may failto heal while others get healed due to their genetic make-up.Polymorphism may influence a drug’s action by changing itspharmacokinetics and pharmacodynamics. Genetic influences onmetabolism interacts with other intrinsic such as physiologic andextrinsic like environmental features of a person to determine theresult from treatment with any pharmacologic agent (Mo SL, 2009).

References

Allen F.Shaughnessy, P. (2008). Clinical Pharmacology. cambridge: Tufts niversity.

Ian Roberts, H. S. (2012). Antifibrinolytic Drugs fo Acute Traumatic injury. PubMed, 36-45.

Kalow W, T. B. (1998). omparison for inter and intra individual variations can subsitute for twin studys in drug research. Phamacogenetics, 283-289.

Mo SL, e. (2009). Subsrtate Specificity, Regulation and Polymorphism of human Cytochrome. Curr Drug Metab, 450.

Close Menu